Regeneron, Alexion Big-Cap Biotechs Sales Seen Rising
Big-cap biotechs Regeneron (REGN) and Alexion (ALXN) are both set to report Q4 results before the open Thursday, and both are expected to report double- or even triple-digit sales and earnings growth. Analysts expect Regeneron to have the steeper sales growth, as it's still ramping up its vision-loss drug Eylea after its approval in November 2011. Analysts polled by Thomson Reuters expect revenue of $392.64 million, up 219% from the year-earlier
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here